Genentech announces positive data from Phase III Archway study of Port Delivery System (PDS) for ranibizumab in treatment of neovascular age-related macular degeneration

RCT compared the 6-monthly permanent refillable eye implant to monthly intravitreal injections of ranibizumab. The primary endpoint (change in best-corrected visual acuity score from baseline at average of week 36 and week 40) was met among patients with the PDS.

Biospace Inc.